EpiCept Seeks Primary Listing Status on OMX Stockholm Exchange TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))-- Regulatory News: EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that it has applied for a primary listing on the Nasdaq OMX Stockholm Exchange in recognition of the Company's large Swedish shareholding base and the historical trading volume of the Company's common stock on the Exchange. Presently, the Company maintains a secondary listing on the Exchange, the status of which is dependent on the Company's continued listing on a recognized national securities exchange in the United States. A decision on its application is expected within the next several months. EpiCept President and CEO Jack Talley commented; “We have recognized for some time the importance of the trading activity generated by our OMX Stockholm listing, and the many shareholders who utilize the OMX Stockholm Exchange to trade their EpiCept shares every day. We are seeking this change in status to give us the flexibility to consider more broadly the needs of our diverse shareholders in Sweden as well as the United States.” If the change in status is approved, the continued listing of the Company's common stock on the Nasdaq Stockholm OMX Exchange will no longer be linked to its continued listing on the Nasdaq Capital Market or on any other national securities exchange. About EpiCept Corporation EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, approved in the EU and Israel for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. In the United States, a pivotal trial is scheduled to commence in 2011. The Company has two other oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies. Forward-Looking Statements This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risks associated with our ability to continue to meet our obligations under our existing debt agreements, the risk that our application to change our listing status on the Nasdaq OMX Stockholm Exchange may not be approved, the risk that our securities may be delisted from The Nasdaq Capital Market, the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, the risk that Ceplene®will not receive regulatory approval or marketing authorization in the United States or Canada, the risk that Ceplene® will not achieve significant commercial success, the risk that any required post-approval clinical study for Ceplene®will not be successful, the risk that we will not be able to maintain our final regulatory approval or marketing authorization for Ceplene®, the risk that Azixa™ will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myrexis, the risk that the development of our other apoptosis product candidates will not be successful, the risk that clinical trials for AmiKet™ or crolibulinTMwill not be successful, the risk that AmiKet™ or crolibulinTMwill not receive regulatory approval or achieve significant commercial success, the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that we will not obtain approval to market any of our product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A% 2F%2Fus.lrd.yahoo.com%2F_ylt%3DAgfqFPfVOEK5M4_Rv8aJvhTjba9_%3B_ylu%3DX3o DMTEzM2pvaWgxBHBvcwMyBHNlYwNuZXdzYXJ0Ym9keQRzbGsDd3d3c2VjZ292%2FSIG%3D15 t064n6f%2F**http%253A%2Fcts.businesswire.com%2Fct%2FCT%253Fid%3Dsmartlin k%2526url%3Dhttp%25253A%25252F%25252Fwww.sec.gov%2526esheet%3D6170045%25 26lan%3Den_US%2526anchor%3Dwww.sec.gov%2526index%3D2%2526md5%3D61ec7b720 44301e411e3335754ee5c07&esheet=6769705&lan=en-US&anchor=www.sec.gov&inde x=1&md5=2c4fa0c98e896e448b0e4ddf9f27721d) or at www.epicept.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http %3A%2F%2Fus.lrd.yahoo.com%2F_ylt%3DAhBuoawHw6iS3RhJOH9dNNfjba9_%3B_ylu%3 DX3oDMTE2OGhhcWs4BHBvcwMzBHNlYwNuZXdzYXJ0Ym9keQRzbGsDd3d3ZXBpY2VwdGNv%2F SIG%3D1659oglun%2F**http%253A%2Fcts.businesswire.com%2Fct%2FCT%253Fid%3D smartlink%2526url%3Dhttp%25253A%25252F%25252Fwww.epicept.com%2526esheet% 3D6170045%2526lan%3Den_US%2526anchor%3Dwww.epicept.com%2526index%3D3%252 6md5%3D8b3a48c3367e26fcfbd15295b6d82118&esheet=6769705&lan=en-US&anchor= www.epicept.com&index=2&md5=285adff98b1d30aec1b917c4f0ebdbff). You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. *Azixa is a registered trademark of Myrexis, Inc. EPCT-GEN EpiCept Corporation: Robert W. Cook, 914-606-3500 rcook@epicept.com (rcook@epicept.com) or Media: Feinstein Kean Healthcare Greg Kelley, 617-577-8110 gregory.kelley@fkhealth.com (gregory.kelley@fkhealth.com) or Investors: Lippert/Heilshorn & Associates Kim Sutton Golodetz, 212-838-3777 kgolodetz@lhai.com (kgolodetz@lhai.com) or Bruce Voss, 310-691-7100 bvoss@lhai.com (bvoss@lhai.com)
EpiCept Seeks Primary Listing Status on OMX Stockholm Exchange
| Source: Immune Pharmaceuticals Inc
Attachments
